Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales Hims & Hers, the telehealth company that has seen a staggering 458% rally in its stock price, is facing a significant challenge as FDA regulations undercut its weight-loss drug business. This unexpected turn of events has put the company in a tough spot, testing […]
Category: Telehealth
Back To Top